Treatment-resistant Schizophrenia Clinical Trial
Official title:
Deep Brain Stimulation of the Ventral Hippocampus in Treatment-resistant Schizophrenia: Exploring the Glutamatergic/GABAergic Mechanisms
The goal of this clinical trial is to assess the efficacy and safety of hippocampus-targeted deep brain stimulation (DBS) in treatment-resistant schizophrenia. The main question it aims to answer are: - whether patients with treatment-resistant schizophrenia can benefit from hippocampus-targeted DBS; - what is the neural and electrophysiological mechanism underlying the treatment effect of hippocampus-targeted DBS.
The first phase of the study will consist of DBS surgery. Participants will receive electrodes implantation in bilateral ventral hippocampus. Continuous stimulation will be applied to optimize and individualize the stimulus parameters. This period is anticipated between 3 and 6 months. The next phase will consist of the crossover study. Patients who respond to DBS will be randomly assigned to two groups, for a period of 3 months: on stimulation group and off stimulation group. Patients will then be crossed over to the other group for a further 3 months. Participants will receive PET-CT, clinical assessment and cognitive tests at the main study points to evaluate treatment efficacy and patient tolerance, and to reveal the underlying mechanism of the treatment effect of DBS. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03076346 -
Neural Biomarkers of Clozapine Response
|
||
| Completed |
NCT03148639 -
Virtual Reality Therapy for Treatment-resistant Auditory Hallucinations in Schizophrenia
|
N/A | |
| Completed |
NCT01431326 -
Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care
|
||
| Recruiting |
NCT06270108 -
The Role of Glutamatergic Function in the Pathophysiology of Treatment-resistant Schizophrenia
|
Early Phase 1 | |
| Not yet recruiting |
NCT06060886 -
Multidisciplinary Design to Optimize Schizophrenia Treatment Based on Multi-omics Data and Systems Biology Analysis
|
Phase 4 | |
| Completed |
NCT01105481 -
Amisulpride Augmentation Therapy for Clozapine-resistant Schizophrenic Patients
|
Phase 4 | |
| Recruiting |
NCT02361554 -
Deep Brain Stimulation in Treatment Resistant Schizophrenia
|
N/A | |
| Recruiting |
NCT05299749 -
Real-time fMRI Neurofeedback in Patients With Schizophrenia and Auditory Hallucinations
|
N/A | |
| Completed |
NCT03585127 -
Avatar Therapy in Comparison to Cognitive Behavioral Therapy for Treatment-resistant Schizophrenia
|
N/A | |
| Not yet recruiting |
NCT05259306 -
Low-Intensity Focused Ultrasound Neuromodulation of the Mediodorsal Thalamus for Treatment-Resistant Schizophrenia
|
N/A | |
| Terminated |
NCT03230864 -
Efficacy of Lu AF35700 in Patients With Early-in-disease or Late-in-disease Treatment-resistant Schizophrenia
|
Phase 3 | |
| Recruiting |
NCT05337904 -
Deep Brain Stimulation Recovery in Treatment-Resistant Schizophrenia
|
N/A | |
| Terminated |
NCT03868839 -
Telmisartan Pilot Study on Treatment Resistant Schizophrenia
|
Phase 2 | |
| Not yet recruiting |
NCT04528095 -
SMART Design to Compare Antipsychotic Treatments in Treatment-Resistant Schizophrenia
|
Phase 3 | |
| Not yet recruiting |
NCT06128408 -
The Characteristics of Treatment Resistant Schizophrenia From the Illness Onset
|
||
| Recruiting |
NCT05074732 -
Dundrum Forensic Redevelopment Evaluation Study: D-FOREST Study.
|
||
| Completed |
NCT03983018 -
Rituximab for Schizophrenia Spectrum Disorder (RITS-PS-2019)
|
Phase 1 | |
| Recruiting |
NCT05741502 -
An Exploratory Analysis of Immune and Inflammatory Response Associated With Clozapine
|
Phase 4 | |
| Recruiting |
NCT04054778 -
Comparaison of Avatar Therapy to Cognitive Behavioral Therapy in Schizophrenia With Treatment Refractory Hallucinations
|
N/A |